Финголимод (Fingolimod)
Международное непатентованное наименование
Финголимод (Fingolimod)
Торговое наименование
Гилениа, Несклер, Модена, Лифеспан
Производитель, страна
Novartis, Switzerland; БиоИнтегратор, Россия; Фармасинтез, Россия; Биокад, Россия; и др.
Лекарственная форма
капсулы, 0,5 мг
Механизм действия
It is derived from myriocin (ISP-1), a metabolite of the fungus Isaria sinclairii. It is a structural analogue of sphingosine and is phosphorylated by sphingosine kinases in the cell (most importantly sphingosine kinase 2). The molecular biology of phospho-fingolimod is thought to lie in its activity at one of the five sphingosine-1-phosphate receptors, S1PR1. Phospho-fingolimod causes the internalization of S1P receptors, which sequesters lymphocytes in lymph nodes, preventing them from moving to the central nervous system and causing a relapse of multiple sclerosis.
Опыт использования
FDA-approved since 2010, approved to treat multiple sclerosis.
Публикации COVID-19
Neurol Ther. 2019 Dec;8(2):231-240. DOI: 10.1007/s40120-019-00162-7.
Клинические исследования
1.
Название протокола
Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)
Дата начала и окончания КИ
February 22, 2020 - July 1, 2020
Название организации, проводящей КИ
First Affiliated Hospital of Fujian Medical University
Страны
China
Фаза
II
Кол-во пациентов
30